Want to see CADL full AI Analyst Report?
CADL Stock Chart & Stats
$13.28
$0.40(4.18%)
At close: 4:00 PM EDT
$13.28
$0.40(4.18%)
Day’s Range― - ―
52-Week Range$4.35 - $14.00
Previous Close$10.1
Volume1.27M
Average Volume (3M)1.22M
Market Cap
$983.26M
Enterprise Value$611.50
Total Cash (Recent Filing)$201.56M
Total Debt (Recent Filing)$49.52M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 05, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding76,518,560
10 Day Avg. Volume1,278,414
30 Day Avg. Volume1,218,262
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)5.76
Price to Sales (P/S)0.00
P/FCF Ratio-7.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.67Price Target Upside55.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Oncology Immunotherapy PipelineMultiple locally delivered viral immunotherapy programs across solid tumors diversify clinical opportunity. Progress in one or more indications could support future partnering, funding access, and commercialization potential.
Solid Equity Base And Moderate LeverageThe equity base provides some balance-sheet support relative to current debt, while moderate leverage limits immediate interest and repayment pressure. This offers financial flexibility as clinical development continues, despite ongoing cash needs.
Board Continuity And Financial OversightConfirmed board continuity and auditor ratification reduce governance uncertainty during a capital-intensive clinical stage. Stable oversight can support execution, reporting discipline, and consistent strategic management as programs advance.
Bears Say
No Recurring Product RevenueWithout commercialized products, the company lacks recurring operating revenue to fund research and development. Continued dependence on financing, grants, or collaborations leaves results highly exposed to clinical timing and capital availability.
Widening Losses And Weak Operating LeverageLosses have widened substantially while revenue remains absent, indicating that development spending is not yet producing operating leverage. Sustained earnings pressure can increase dilution risk and constrain the company’s ability to self-fund trials.
Accelerating Cash Burn And Rising Financing RiskThe worsening cash deficit increases the funding required to maintain clinical programs. Combined with sharply higher debt versus 2025, this raises refinancing, dilution, and execution risks if meaningful development or partnering catalysts do not emerge.
Candel Therapeutics News
CADL FAQ
What was Candel Therapeutics’s price range in the past 12 months?
Candel Therapeutics lowest stock price was $4.35 and its highest was $14.00 in the past 12 months.
What is Candel Therapeutics’s market cap?
Candel Therapeutics’s market cap is $983.26M.
When is Candel Therapeutics’s upcoming earnings report date?
Candel Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 62 days.
How were Candel Therapeutics’s earnings last quarter?
Candel Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.238 by -$0.282.
Is Candel Therapeutics overvalued?
According to Wall Street analysts Candel Therapeutics’s price is currently Undervalued.
Does Candel Therapeutics pay dividends?
Candel Therapeutics does not currently pay dividends.
What is Candel Therapeutics’s EPS estimate?
Candel Therapeutics’s EPS estimate is -0.33.
How many shares outstanding does Candel Therapeutics have?
Candel Therapeutics has 76,518,560 shares outstanding.
What happened to Candel Therapeutics’s price movement after its last earnings report?
Candel Therapeutics reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.238. Following the earnings report the stock price went up 10.487%.
Which hedge fund is a major shareholder of Candel Therapeutics?
Currently, no hedge funds are holding shares in CADL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Candel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.67 (55.62% Upside)
$20.67 (55.62% Upside)
Blogger Sentiment
Bullish
CADL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 98.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.9%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
125.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
96.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Candel Therapeutics
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
CADL Stock 12 Month Forecast
Average Price Target
$20.67
▲(55.62% Upside)
Technical Analysis
CytomX Therapeutics
―
Replimune Group
―
Immatics
―
Lyell Immunopharma
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
9.06% Insiders
16.61% Mutual Funds
26.00% Other Institutional Investors
36.09% Public Companies and
Individual Investors